ASPEN PHARMACARE HOLDINGS LIMITED - Opening of Eur15 May 2017
APN 201705150028A
Opening of European Commission proceedings

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)(“Aspen Holdings”)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen”)



OPENING OF EUROPEAN COMMISSION PROCEEDINGS

Aspen confirms that the European Commission has opened proceedings to investigate certain
actions of Aspen Holdings and certain of its European subsidiaries.

While Aspen is not currently in a position to comment on these proceedings, it reaffirms its
commitment to fair and open competition in markets in the European Union and around the world.
Aspen takes compliance with competition laws very seriously and will work constructively with the
European Commission in its process.

Shareholders are advised that any material developments in these proceedings will be
communicated through SENS. Shareholders should exercise care when reacting to information on
this matter which has not been released by Aspen Holdings.

Durban
15 May 2017

Sponsor:
Investec Bank Limited


About Aspen

Aspen is a leading global player in specialty, branded and generic pharmaceuticals with an extensive
basket of products that provide treatment for a broad spectrum of acute and chronic conditions
experienced through all stages of life. Aspen continues to increase the number of lives benefitting
from its products, reaching more than 150 countries.

Aspen has a strong presence in both emerging and developed countries. Its emerging market
footprint includes Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe and the
Commonwealth of Independent States, comprising Russia and the former Soviet Republics. From a
developed world perspective Aspen is one of the leading pharmaceutical companies in Australia and
has a growing presence in other developed countries, most notably in Western Europe.

Aspen operates with an established business presence in approximately 50 countries spanning 6
continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities
across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent
global regulatory agencies including the FDA, TGA and EMA. Aspen’s manufacturing capabilities are
scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-
solids, steriles, biologicals, APIs and infant nutritionals.
Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies
on this exchange. For more information visit: http://www.aspenpharma.com/

Date: 15/05/2017 12:10:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.